Okamoto Akiko, Nakatsukasa Katsuhiko, Fujita Yoshifumi, Sugimoto Riho, Sakaguchi Kouichi, Taguchi Tetsuya
Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine.
Gan To Kagaku Ryoho. 2015 Mar;42(3):343-6.
Paclitaxel combined with bevacizumab yields significantly better progression-free survival (PFS) in patients with metastatic breast cancer than paclitaxel alone. Here, we report a case of stage IV breast cancer with multiple liver, lung, and bone metastases maintaining a long-term partial response (PR) with tri-weekly paclitaxel plus bevacizumab administration. A 46- year-old woman treated with endocrine therapy for 21 months for multiple metastases in her lungs and bones detected 4 years after surgery for left breast cancer was referred to our hospital. New metastases were discovered in her liver. She received paclitaxel (l 90 mg/m/(2)) on days 1, 8, and 15 combined with bevacizumab (10 mg/kg) on days 1 and 15 every 4 weeks. However, during the first 3 courses, the administration of paclitaxel on day 8 was postponed to 1 to 2 weeks because of severe neutropenia. We began tri-weekly administration of paclitaxel plus bevacizumab. She continued receiving the treatment for about 1 year, without severe side effects. The PR state with good performance status was maintained. We suggest that the tri-weekly administration of paclitaxel plus bevacizumab is an effective way to maintain long-term efficacy.
与单独使用紫杉醇相比，紫杉醇联合贝伐单抗可使转移性乳腺癌患者的无进展生存期（PFS）显著延长。在此，我们报告一例IV期乳腺癌患者，该患者有多处肝脏、肺部和骨转移，通过每三周一次给予紫杉醇加贝伐单抗治疗，维持了长期部分缓解（PR）。一名46岁女性，因左乳腺癌术后4年发现肺部和骨多处转移，接受了21个月的内分泌治疗，后转诊至我院。发现其肝脏出现新的转移灶。她每4周在第1、8和15天接受紫杉醇（190mg/m²）治疗，并在第1和15天联合使用贝伐单抗（10mg/kg）。然而，在最初的3个疗程中，由于严重的中性粒细胞减少，第8天的紫杉醇给药推迟至1至2周。我们开始每三周一次给予紫杉醇加贝伐单抗。她持续接受治疗约1年，无严重副作用。维持了具有良好身体状况的PR状态。我们认为，每三周一次给予紫杉醇加贝伐单抗是维持长期疗效的有效方法。
